BridgeBio Pharma, a Phase 3 biotech developing therapies for genetic diseases, announced terms for its IPO on Monday.
The Palo Alto, CA-based company plans to raise $225 million by offering 15 million shares at a price range of $14 to $16. At the midpoint of the proposed range, BridgeBio Pharma would command a fully diluted market value of $1.7 billion.
BridgeBio Pharma was founded in 2015 and plans to list on the Nasdaq under the symbol BBIO. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James are the joint bookrunners on the deal. It is expected to price during the week of June 24, 2019.
